"Kirkland & Ellis Advises Curewell Capital on Investment in Wilmington PharmaTech to Expand Manufacturing Capacity"

"Kirkland & Ellis advised Curewell Capital on its investment in Wilmington PharmaTech (WPT), a U.S. contract research and manufacturing organization specializing in small molecule API development. WPT's CEO, Hui-Yin “Harry” Li, will maintain a significant ownership stake and continue to lead the company. The investment will provide growth capital to enhance WPT's manufacturing capacity and capabilities. The transaction was announced on October 21, 2025."

Kirkland & Ellis served as legal counsel to private equity firm Curewell Capital in its investment in Wilmington PharmaTech (WPT), a U.S.-based specialty contract research, development, and manufacturing organization. The transaction, announced on October 21, 2025, will enable WPT to expand its manufacturing capacity and enhance its capabilities in producing a full range of small molecule active pharmaceutical ingredients (APIs) in the U.S. Hui-Yin “Harry” Li, Ph.D., the Founder and CEO of WPT, will maintain a significant ownership stake and continue to lead the company alongside the management team. The Kirkland team involved in this transaction included corporate lawyers Adam Wexner, Marion Racine, Jane Guo, and Yangxier Sui; tax lawyers Rachel Cantor and Rory Minnis; debt finance lawyers Michelle Kilkenney and Alex Bender; and healthcare lawyers Dennis Williams, Will Richmond, and Brian King.

"Kirkland & Ellis Advises Curewell Capital on Investment in Wilmington PharmaTech to Expand Manufacturing Capacity"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads